Geode Capital Management
PPBT

Geode Capital Management’s Purple Biotech PPBT Stock Holding History

Geode Capital Management’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-63
Closed -$5.26K – 4571
2024
Q2 		$5.26K Hold
63
– – ﹤0.01% 4574
2024
Q1 		$8.47K Hold
63
– – ﹤0.01% 4564
2023
Q4 		$9.88K Hold
63
– – ﹤0.01% 4589
2023
Q3 		$14.6K Hold
63
– – ﹤0.01% 4674
2023
Q2 		$17.7K Hold
63
– – ﹤0.01% 4673
2023
Q1 		$22.3K Hold
63
– – ﹤0.01% 4685
2022
Q4 		$17K Hold
63
– – ﹤0.01% 4786
2022
Q3 		$25K Hold
63
– – ﹤0.01% 4883
2022
Q2 		$30K Hold
63
– – ﹤0.01% 4871
2022
Q1 		$50K Hold
63
– – ﹤0.01% 4802
2021
Q4 		$49K Hold
63
– – ﹤0.01% 4863
2021
Q3 		$57K Buy
+63
New +$61K ﹤0.01% 4767

Other funds holding PPBT

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
NSIM
North Star Investment Management Chicago, Illinois $1.84B AUM 28.81% 1-Year Est. Return

Geode Capital Management's PPBT Position: Q3 2024 in Review

Geode Capital Management sold out of Purple Biotech (PPBT) in Q3 2024, closing a stake of 63 shares — an estimated $5.26K sold.

Geode Capital Management first reported a position in PPBT in Q3 2021 and held it in 12 quarters. The position peaked at $57K in Q3 2021. 10 funds tracked by Wall St. Rank hold PPBT as of Q3 2024.

  • Geode Capital Management reported no remaining Purple Biotech position as of Q3 2024 after selling out during the quarter.
  • Geode Capital Management sold 63 Purple Biotech shares in Q3 2024, an estimated $5.26K.
  • Geode Capital Management first reported a position in Purple Biotech in Q3 2021 and held it in 12 quarters.
  • Geode Capital Management's Purple Biotech position peaked at $57K in Q3 2021.
  • 10 funds tracked by Wall St. Rank held Purple Biotech as of Q3 2024.

Based on Geode Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.